Diana Martirosyan

Dr. Diana Martirosyan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NDNune Darbinian
Nune Darbinian
ADArmine Darbinyan
Armine Darbinyan
JSJohn Sinard
John Sinard
GTGabriel Tatevosian
Gabriel Tatevosian
NMNana Merabova
Nana Merabova
MSMichael Selzer
Michael Selzer
Prenatal alcohol exposure can cause developmental abnormalities (fetal alcohol spectrum disorders; FASD), including small eyes, face and brain, and neurobehavioral deficits. These cannot be detected early in pregnancy with available imaging techniques. Early diagnosis could facilitate development of therapeutic interventions. Banked human fetal brains and eyes at 9–22 weeks’ gestation were paired with maternal blood samples, analyzed for morphometry, protein, and RNA expression, and apoptotic signaling. Alcohol (EtOH)-exposed (maternal self-report) fetuses were compared with unexposed controls matched for fetal age, sex, and maternal race. Fetal brain-derived exosomes (FB-E) were isolated from maternal blood and analyzed for protein, RNA, and apoptotic markers. EtOH use by mothers, assessed by self-report, was associated with reduced fetal eye diameter, brain size, and markers of synaptogenesis. Brain caspase-3 activity was increased. The reduction in eye and brain sizes were highly correlated with amount of EtOH intake and caspase-3 activity. Levels of several biomarkers in FB-E, most strikingly myelin basic protein (MBP; r > 0.9), correlated highly with morphological abnormalities. Reduction in FB-E MBP levels was highly correlated with EtOH exposure (p < 1.0 × 10−10). Although the morphological features of FAS appear long before they can be detected by live imaging, FB-E in the mother’s blood may contain markers, particularly MBP, that predict FASD.

Verified
Journal Article
Open access
PDF file
NDNune Darbinian
Nune Darbinian
MHMonica Hampe
Monica Hampe
DMDiana Martirosyan
Diana Martirosyan
ABAhsun Bajwa
Ahsun Bajwa
ADArmine Darbinyan
Armine Darbinyan
MSMichael Selzer
Michael Selzer
Fetal alcohol spectrum disorders (FASDs) are leading causes of neurodevelopmental disability but cannot be diagnosed early in utero. Because several microRNAs (miRNAs) are implicated in other neurological and neurodevelopmental disorders, the effects of EtOH exposure on the expression of these miRNAs and their target genes and pathways were assessed. In women who drank alcohol (EtOH) during pregnancy and non-drinking controls, matched individually for fetal sex and gestational age, the levels of miRNAs in fetal brain-derived exosomes (FB-Es) isolated from the mothers’ serum correlated well with the contents of the corresponding fetal brain tissues obtained after voluntary pregnancy termination. In six EtOH-exposed cases and six matched controls, the levels of fetal brain and maternal serum miRNAs were quantified on the array by qRT-PCR. In FB-Es from 10 EtOH-exposed cases and 10 controls, selected miRNAs were quantified by ddPCR. Protein levels were quantified by ELISA. There were significant EtOH-associated reductions in the expression of several miRNAs, including miR-9 and its downstream neuronal targets BDNF, REST, Synapsin, and Sonic hedgehog. In 20 paired cases, reductions in FB-E miR-9 levels correlated strongly with reductions in fetal eye diameter, a prominent feature of FASDs. Thus, FB-E miR-9 levels might serve as a biomarker to predict FASDs in at-risk fetuses.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KDKatherine L Doktor
Katherine L Doktor
MKMadeline King
Madeline King
DMDiana Martirosyan
Diana Martirosyan
SMScott R Moore
Scott R Moore
HFHenry S Fraimow
Henry S Fraimow
The majority of reported Serratia infective endocarditis (SIE) in recent years are healthcare-associated. At our urban institution with a high prevalence of people who inject drugs (PWID), we noted an increasing number of Serratia bacteremias (SB) and SIE over the past decade. Our study describes patient factors associated with SB and SIE. We evaluated charts of patients with SB at our institution between 2010 and 2022 to determine risk factors and clinical outcomes. There were 157 episodes of SB in 153 patients. The majority were male (57%), white (57%) with a mean age 53. The most common source of infection was catheter- line-associated infection (CLABSI) (27%), followed by primary bacteremia (19%). Twenty-six % were PWID with younger mean age (41 years). PWID had lower mortality than non-PWID (23% vs 44%, p=0.023). Sixty-nine (46%) were admitted to the intensive care unit (ICU) with significantly higher mortality associated with ICU admission (48% vs 8%, p=0.015). Echocardiograms were performed in 59% (93/157) of SB episodes and 14% had SIE (13/93). Most SIE (69%) occurred after 2017 with 89% in PWID (8/9). The most common comorbidity with SIE was injection drug use (IDU) (69%). All non-IDU SIE were CLABSI-related; 75% had hemodialysis catheters. Tricuspid valves were infected in 46%. Sixty-two % of those with SIE had septic emboli. Most SIE (69%) required ICU admission. Overall mortality was 31%. Only 2% (3/153) of patients with SB developed antibiotic resistance on therapy. Clinical worsening or failure occurred in 20% (32/157). Only 5% (7/157) had microbiologic recurrence within 30 days. 32% of discharged patients re-presented to the hospital within 30 days. Almost all deaths (92%) occurred during initial admission. Patients with SB were quite ill with a high rate of in-hospital mortality; over half of the patients had antibiotic exposures prior to developing SB or presented within 90 days of a prior hospitalization. The majority of SB were line-associated, including all episodes of non-IDU SIE. IDU was the second most common comorbidity and PWID with SB had a higher rate of SIE, with most IDU-associated SIE diagnosed after 2017. This aligns with other recent studies documenting the increased prevalence of SB, especially in PWID. Madeline King, PharmD, La Jolla: Advisor/Consultant|Shionogi: Advisor/Consultant